drugset / Trial / NCT00006080
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Phase 2
Completed
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent malignant glioma.
Timeline
- Start
- 2000-09-25
- Primary completion
- 2004-09-14
- Completion
- 2004-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | fenretinide | Small molecule | 600 mg/m2 | Oral |
| Subject | fenretinide | Small molecule | 900 mg/m2 | Oral |